Sarepta Therapeutics Inc (NASDAQ:SRPT) was the recipient of some unusual options trading activity on Friday. Traders bought 22,555 put options on the company. This represents an increase of 2,651% compared to the typical daily volume of 820 put options.

Shares of Sarepta Therapeutics (NASDAQ:SRPT) opened at $61.52 on Monday. The company has a debt-to-equity ratio of 0.04, a current ratio of 10.44 and a quick ratio of 9.52. Sarepta Therapeutics has a twelve month low of $26.26 and a twelve month high of $61.89. The firm has a market cap of $3,980.00, a PE ratio of -30.16 and a beta of 1.37.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported ($0.20) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.86) by $0.66. Sarepta Therapeutics had a negative net margin of 112.08% and a negative return on equity of 51.72%. The business had revenue of $45.95 million for the quarter, compared to analysts’ expectations of $41.29 million. During the same quarter last year, the company earned ($0.95) EPS. analysts expect that Sarepta Therapeutics will post -3.07 earnings per share for the current year.

A number of research firms have commented on SRPT. BidaskClub upgraded shares of Sarepta Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday. HC Wainwright restated a “buy” rating and issued a $75.00 price target on shares of Sarepta Therapeutics in a research report on Tuesday, January 9th. Zacks Investment Research downgraded shares of Sarepta Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, January 5th. Janney Montgomery Scott initiated coverage on shares of Sarepta Therapeutics in a research report on Wednesday, January 3rd. They issued a “buy” rating and a $75.00 price target on the stock. Finally, Oppenheimer restated a “buy” rating and issued a $76.00 price target on shares of Sarepta Therapeutics in a research report on Wednesday, December 27th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and eighteen have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $63.88.

In other Sarepta Therapeutics news, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of the stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $55.89, for a total transaction of $372,618.63. Following the transaction, the director now directly owns 13,333 shares in the company, valued at approximately $745,181.37. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Shamim Ruff sold 10,000 shares of the stock in a transaction on Monday, November 6th. The shares were sold at an average price of $55.00, for a total transaction of $550,000.00. Following the transaction, the senior vice president now owns 37,045 shares in the company, valued at $2,037,475. The disclosure for this sale can be found here. Corporate insiders own 9.60% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in SRPT. Jennison Associates LLC increased its holdings in shares of Sarepta Therapeutics by 103.9% in the 3rd quarter. Jennison Associates LLC now owns 1,143,853 shares of the biotechnology company’s stock worth $51,885,000 after acquiring an additional 582,894 shares during the period. Alyeska Investment Group L.P. acquired a new stake in shares of Sarepta Therapeutics in the 3rd quarter worth about $26,011,000. Voya Investment Management LLC increased its holdings in shares of Sarepta Therapeutics by 2,786.1% in the 2nd quarter. Voya Investment Management LLC now owns 568,525 shares of the biotechnology company’s stock worth $19,165,000 after acquiring an additional 548,826 shares during the period. Gilder Gagnon Howe & Co. LLC increased its holdings in shares of Sarepta Therapeutics by 3,599.4% in the 3rd quarter. Gilder Gagnon Howe & Co. LLC now owns 534,087 shares of the biotechnology company’s stock worth $24,226,000 after acquiring an additional 519,650 shares during the period. Finally, HealthCor Management L.P. increased its holdings in shares of Sarepta Therapeutics by 31.1% in the 2nd quarter. HealthCor Management L.P. now owns 2,031,890 shares of the biotechnology company’s stock worth $68,495,000 after acquiring an additional 481,890 shares during the period. 82.02% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Sarepta Therapeutics Sees Unusually High Options Volume (SRPT)” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this news story on another site, it was illegally copied and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this news story can be read at https://www.americanbankingnews.com/2018/01/15/sarepta-therapeutics-sees-unusually-high-options-volume-srpt-2.html.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.